Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% ...

Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

ACTIONS TO ADDRESS THE SITUATION: On 4 February 2025, The Ministry of Health of Ethiopia issued a circular to all regional health bureau to assure regional health offices that the government will step ...

People will no longer receive condoms to prevent new HIV infections and sexually transmitted infections.

The following is a summary of “Multimodality Therapy Including Pleurectomy/Decortication in Pleural Mesothelioma: Long-Term ...

"Renal-dose" dopamine is widely used in clinical practice despite the controversial benefit in the prophylaxis and treatment of acute renal failure. Goldberg et al. [1] were the first to ...